Mark Hillman Top Holdings Analysis: Strategic Portfolio Allocation in 2026
Mark A. Hillman's Hillman Value Fund portfolio, valued at $144 million as of March 31, 2026, features significant allocations to healthcare, consumer staples, and industrials stocks with varying share changes.
As of March 31, 2026, Mark A. Hillman's Hillman Value Fund portfolio, valued at $144,004,744, demonstrates a strategic allocation across diverse sectors, with significant positions in Healthcare, Basic Materials, and Communication Services. The fund manager's approach is evident in the top holdings, which account for approximately 35% of the total portfolio value.
Healthcare remains a cornerstone of Hillman's investment strategy, with five of the top ten holdings belonging to this sector. BIOGEN INC (BIIB) stands out with a 3.76% allocation, followed closely by GSK PLC (GSK) at 3.73% and PFE (3.66%) and ZBH (3.50%) rounding out the Healthcare top five. Despite a significant reduction in shares (-22.98%), BIOGEN's position remains intact, suggesting confidence in its long-term prospects. Similarly, GSK saw a substantial share reduction (-31.28%), while PFE also decreased (-13.21%), indicating maturing investment theses or sector rotation within this group.
Consumer staples and industrials form another core pillar of Hillman's portfolio. The fund allocates 3.75% to DUPONT DE NEMOURS INC (DD) in Basic Materials and 3.74% to WARNER BROS DISCOVERY INC (WBD) in Communication Services. Notably, DD experienced a substantial increase in holdings (+65.65%) during the period, signaling renewed confidence in its business model or valuation. Conversely, WBD saw a significant reduction (-40.64%) in its position, reflecting either underperformance or a strategic shift away from media assets.
The fund also maintains substantial exposure to other sectors.INTERNATIONAL FLAVORS&FRAGRA (IFF) in Basic Materials holds a 3.67% allocation, while CARMAX INC (KMX) in Consumer Cyclical accounts for 3.15%. Both show moderate share changes, with IFF decreasing slightly (-8.19%) and KMX increasing (+19.34%). Completing the top ten is CVS HEALTH CORP (CVS) at 3.36% in Healthcare, which saw a moderate share reduction (-18.09%).
Hillman's strategy appears focused on established businesses with value characteristics, evident in the allocations to companies like DD, IFF, KMX, PFE, and ZBH. The mixed share changes observed across the portfolio—from significant increases in DD to substantial decreases in BIIB and WBD—suggest a dynamic investment approach where underperforming positions are trimmed while opportunities in other areas are capitalized on. For detailed insights into Mark Hillman's investment approach, readers can visit the investor profile at Mark A. Hillman's profile.
To understand the specific investment cases for each company, detailed analysis is available. For instance, learn more about BIOGEN INC (BIIB) at BIIB, DUPONT DE NEMOURS INC (DD) at DD, WARNER BROS DISCOVERY INC (WBD) at WBD, GSK PLC (GSK) at GSK, INTERNATIONAL FLAVORS&FRAGRA (IFF) at IFF, PFIZER INC (PFE) at PFE, ZIMMER BIOMET HOLDINGS INC (ZBH) at ZBH, CVS HEALTH CORP (CVS) at CVS, BROWN FORMAN CORP (BF-B) at BF-B, and CARMAX INC (KMX) at KMX.